- NCIt
- C9466
Loading cancer entity…
Loading cancer entity…
Clinical trials
994 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (85)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05099978 | Asian Multicenter Prospective Study of ctDNA Sequencing(A-TRAIN) | unknown | — | 506 | National Cancer Center, JapanOTHER_GOV | 8 | Sep 4, 2024 | clinicaltrials |
| NCT06170021 | Occurrence of Radiation-induced Otitis Media in Nasopharyngeal Carcinoma Patients After Intensity Modulated Radiotherapy | unknown | — | 215 | Sun Yat-sen UniversityOTHER | 1 | Aug 6, 2024 |
| clinicaltrials |
| NCT06523933 | Distribution of Bacteria in OME After Radiotherapy For NPC. | unknown | — | 234 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Jul 26, 2024 | clinicaltrials |
| NCT06486220 | PFLL Combined With PD-1 Antibody With or Without FMT for Oligometastatic NPC,a Phase III ,Open, Randomized Clinical Trial. | unknown | Phase 3 | 96 | Yun-fei XiaOTHER | 0 | Jul 3, 2024 | clinicaltrials |
| NCT06480903 | Exploratory Study of EBV DNA Titre Clearance Whilst on Proton Beam Therapy(ClearED) | unknown | — | 10 | The Christie NHS Foundation TrustOTHER | 0 | Jun 28, 2024 | clinicaltrials |
| NCT06472024 | Assessing Manual Acupuncture's Impact on Mucositis From Nasopharynx Cancer Radiotherapy: A Visual Analogue Scale (VAS) and Quality of Life Study | unknown | N/A | 30 | Indonesia UniversityOTHER | 0 | Jun 26, 2024 | clinicaltrials |
| NCT06442709 | Combined Anti-IL6R and Anticoagulation Therapy in Advanced NPC Patients | unknown | N/A | 100 | Affiliated Hospital of Nantong UniversityOTHER | 1 | Jun 4, 2024 | clinicaltrials |
| NCT05955105 | A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies | unknown | Phase 1 / Phase 2 | 200 | Innolake BiopharmINDUSTRY | 1 | May 21, 2024 | clinicaltrials |
| NCT04444869 | Testing Less Intensive Radiation With Chemotherapy to Treat Low-risk Patients With HPV-positive Oropharyngeal Cancer(ENID) | unknown | Phase 2 | 28 | University of Missouri-ColumbiaOTHER | 1 | May 17, 2024 | clinicaltrials |
| NCT04557020 | Adding PD-1 Inhibitor to Neoadjuvant and Adjuvant for NPC | unknown | Phase 3 | 200 | Jiangxi Provincial Cancer HospitalOTHER | 1 | May 1, 2024 | clinicaltrials |
| NCT05858385 | Predictive Study on Acute Radiation Induced Oral Mucositis in Nasopharyngeal Carcinoma Patients | unknown | — | 700 | Affiliated Cancer Hospital & Institute of Guangzhou Medical UniversityOTHER | 1 | Apr 30, 2024 | clinicaltrials |
| NCT06364826 | Sintilimab Combination Therapy Plus IMRT in Nasopharyngeal Carcinoma | unknown | Phase 2 | 60 | Zhejiang Cancer HospitalOTHER | 0 | Apr 15, 2024 | clinicaltrials |
| NCT06268600 | The Protection of Thyroid Function in IMRT for Nasopharyngeal Carcinoma | unknown | N/A | 320 | Jiangxi Provincial Cancer HospitalOTHER | 1 | Apr 11, 2024 | clinicaltrials |
| NCT04830267 | The Efficacy of Camrelizumab Plus Stereotactic Body Radiotherapy in R/M NPC | unknown | Phase 2 | 39 | Chongqing University Cancer HospitalOTHER | 1 | Mar 28, 2024 | clinicaltrials |
| NCT06097793 | KSD-101 Therapy for EBV-associated Nasopharyngeal Carcinoma: an Exploratory Clinical Trial | unknown | Early Phase 1 | 12 | Kousai Bio Co., Ltd.OTHER | 1 | Mar 12, 2024 | clinicaltrials |
| NCT06259721 | Anti-PD1 Monoclonal Antibody Combined With Nimotuzumab and Capecitabine in Patients With First-line Platinum-resistant Recurrent/Metastatic Nasopharyngeal Carcinoma | unknown | Phase 2 | 22 | Jiangxi Provincial Cancer HospitalOTHER | 1 | Mar 7, 2024 | clinicaltrials |
| NCT05011227 | Camrelizumab and Chemotherapy Combined With Endoscopic Surgery for Recurrent Nasopharyngeal Carcinoma | unknown | Phase 2 | 100 | Eye & ENT Hospital of Fudan UniversityOTHER | 1 | Mar 6, 2024 | clinicaltrials |
| NCT01819480 | Efficacy and Safety of TORS for SCCA | unknown | N/A | 110 | Katherine L FedderOTHER | 1 | Feb 9, 2024 | clinicaltrials |
| NCT05893810 | Bacterial Decolonization to Prevent Radiation-induced Oral Mucositis | unknown | Phase 3 | 176 | Jiangxi Provincial Cancer HospitalOTHER | 1 | Feb 8, 2024 | clinicaltrials |
| NCT03708822 | Study of Docetaxel and Cisplatin Combined With Nimotuzumab As First-Line Treatment in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma | unknown | Phase 2 | 48 | Sun Yat-sen UniversityOTHER | 1 | Jan 18, 2024 | clinicaltrials |
| NCT04398524 | A Phase II Study of Cemiplimab and ISA101b in Patients With Recurrent/Metastatic HPV16 Positive OPC | unknown | Phase 2 | 65 | ISA PharmaceuticalsINDUSTRY | 9 | Jan 16, 2024 | clinicaltrials |
| NCT06032767 | Prospective Observational Study to Predict Severe Oral Mucositis Associated With Chemoradiotherapy in Nasopharyngeal Carcinoma Based on Deep Learning | unknown | — | 480 | Sun Yat-sen UniversityOTHER | 1 | Jan 5, 2024 | clinicaltrials |
| NCT03669718 | A Randomized Phase 2 Study of Cemiplimab ± ISA101b in HPV16-Positive OPC | unknown | Phase 2 | 194 | ISA PharmaceuticalsINDUSTRY | 13 | Dec 29, 2023 | clinicaltrials |
| NCT06156878 | PD-1 Inhibitor Plus Anti-EGFR Therapy And Radiotherapy in Locally Advanced NPC Resistant to Induction Chemotherapy | unknown | Phase 2 | 41 | Fudan UniversityOTHER | 1 | Dec 5, 2023 | clinicaltrials |
| NCT05576272 | A Phase II/III Trial to Evaluate the Efficacy and Safety of QL1706 in Patients With Nasopharyngeal Carcinoma | unknown | Phase 2 / Phase 3 | 460 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Nov 22, 2023 | clinicaltrials |
| NCT06136962 | Nasopharyngeal Carcinoma Treated With Reduced Volume Intensity Modulated Radiation Therapy:10-Year Outcome and Late Toxicity, Quality of Life | unknown | — | 500 | Fujian Cancer HospitalOTHER_GOV | 1 | Nov 18, 2023 | clinicaltrials |
| NCT06138483 | A New Mutational and Epigenetic Signature to Predict Early OPSCC Relapse | unknown | — | 267 | Centro di Riferimento Oncologico - AvianoOTHER | 1 | Nov 18, 2023 | clinicaltrials |
| NCT06129201 | Development of a Machine Learning Model for Nasopharyngeal Carcinoma Screening Based on Tongue Imaging | unknown | — | 5,000 | Fifth Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | Nov 13, 2023 | clinicaltrials |
| NCT05202626 | Detection and Biopsy Guidance of Nasopharyngeal Carcinoma Based on Artificial Intelligence and Endoscopic Images | unknown | — | 100 | Chinese Academy of SciencesOTHER_GOV | 1 | Oct 17, 2023 | clinicaltrials |
| NCT05626829 | Tranilast as a Radiosensitizer in Reradiation of Nasopharyngeal Carcinoma | unknown | Phase 2 | 18 | Jian GuanOTHER | 1 | Oct 6, 2023 | clinicaltrials |
| NCT05520814 | PD-1 Inhibitors Plus Chemoradiotherapy for Metastatic Nasopharyngeal Carcinoma: an Open-label Single-arm, Phase II Trial | unknown | Phase 2 | 50 | Sichuan Cancer Hospital and Research InstituteOTHER | 1 | Sep 21, 2023 | clinicaltrials |
| NCT04593186 | Magnifying NBI for Occult NPC | unknown | N/A | 246 | Chinese University of Hong KongOTHER | 1 | Sep 7, 2023 | clinicaltrials |
| NCT05949749 | A Retrospective Study Reveals the Relationship Between gp42-IgG Epitopes and EBV-associated NPC | unknown | — | 1,000 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Sep 6, 2023 | clinicaltrials |
| NCT05992610 | Induction Treatment in SCC of the Head and Neck Region - Concomitant Chemotherapy and Low-dose Radiotherapy(iCHRTL) | unknown | N/A | 40 | Maria Sklodowska-Curie National Research Institute of OncologyOTHER | 1 | Aug 15, 2023 | clinicaltrials |
| NCT04156698 | Induction Chemotherapy Combined With Immunotherapy for Locally Advanced Hypopharyngeal Carcinoma | unknown | Phase 2 | 51 | Eye & ENT Hospital of Fudan UniversityOTHER | 1 | Aug 9, 2023 | clinicaltrials |
| NCT05981157 | Anrotinib and Tirelizumab in First-line Treatment of RM-NPC | unknown | Phase 2 | 27 | Zhongshan People's Hospital, Guangdong, ChinaOTHER | 1 | Aug 8, 2023 | clinicaltrials |
| NCT02501993 | Nasopharyngeal Carcinoma Screening in Zhongshan City | unknown | — | 25,000 | Zhongshan People's Hospital, Guangdong, ChinaOTHER | 1 | Jul 13, 2023 | clinicaltrials |
| NCT04522050 | Gemcitabine-based Induction Chemotherapy Combined With Concurrent Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma | unknown | Phase 1 | 65 | Fifth Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | Jul 12, 2023 | clinicaltrials |
| NCT03925090 | Phase II Trial of Neoadjuvant and Adjuvant Anti-PD-1 Antibody Toripalimab Combined With CCRT in NPC Patients | unknown | Phase 2 | 150 | Sun Yat-sen UniversityOTHER | 1 | Jul 3, 2023 | clinicaltrials |
| NCT05913414 | Iron Isomaltide for Iron-deficiency Anemia Patients With Locally Advanced Nasopharyngeal Carcinoma | unknown | Phase 2 | 120 | Sun Yat-sen UniversityOTHER | 1 | Jun 22, 2023 | clinicaltrials |
| NCT03855020 | Serial Epstein-Barr Virus DNA Surveillance in Nasopharyngeal Carcinoma Patients | unknown | — | 1,000 | Sun Yat-sen UniversityOTHER | 1 | Jun 18, 2023 | clinicaltrials |
| NCT04072107 | EPstein-barr Virus DNA Response to Systemic Therapy for Treatment Adaptation in High Risk NPC (EP-STAR)(EP-STAR) | unknown | Phase 2 | 110 | Sun Yat-sen UniversityOTHER | 1 | Jun 18, 2023 | clinicaltrials |
| NCT04221516 | Camrelizumab After Completion of Radiotherapy for Oligometastatic Nasopharyngeal Carcinoma | unknown | Phase 2 | 52 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Jun 18, 2023 | clinicaltrials |
| NCT05898256 | Cadonilimab in the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma | unknown | Phase 1 / Phase 2 | 20 | Guangxi Medical UniversityOTHER | 0 | Jun 12, 2023 | clinicaltrials |
| NCT03321539 | Phase Ⅲ Trial of Adjuvant Chemotherapy in Patients With N2-3 Nasopharyngeal Carcinoma | unknown | Phase 3 | 216 | Sun Yat-sen UniversityOTHER | 1 | May 22, 2023 | clinicaltrials |
| NCT05771025 | Effect of Hepatectomy on the Prognosis of Patients With Nasopharyngeal Carcinoma Liver Metastases | unknown | N/A | 55 | Fudan UniversityOTHER | 1 | May 19, 2023 | clinicaltrials |
| NCT04586088 | Apatinib and Camrelizumab in Recurrent or Metastatic Nasopharyngeal Carcinoma With First-line Treatment Failure | unknown | Phase 2 | 58 | Sun Yat-sen UniversityOTHER | 1 | May 6, 2023 | clinicaltrials |
| NCT05229315 | PD-1 Combined With Intensity Modulated Radiation Therapy in the Treatment of Intermediate-risk Nasopharyngeal Carcinoma | unknown | Phase 2 | 45 | XIANG YANQUNOTHER | 1 | Apr 13, 2023 | clinicaltrials |
| NCT05790200 | Cadonilimab (AK104) in the Treatment of Nasopharyngeal Carcinoma | unknown | Phase 2 | 30 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Mar 30, 2023 | clinicaltrials |
| NCT05097209 | Camrelizumab for the Treatment of Locally Advanced Nasopharyngeal Carcinoma | unknown | Phase 2 | 200 | Wei JiangOTHER | 1 | Mar 23, 2023 | clinicaltrials |
Data updated 22 days agoSource updated Sep 4, 2024source: clinicaltrials